ATHX:NASDAQ

Athersys Inc.

Athersys Inc. is a clinical-stage biotechnology company developing MultiStem, a patented, adult-derived "off-the-shelf" stem cell product platform for the cardiovascular, neurological, inflammatory and immune disease areas. The company currently has five clinical stage programs involving MultiStem, including those for treating inflammatory bowel disease (partnered with Pfizer Inc.), ischemic stroke, damage caused by myocardial infarction and for the prevention of graft-versus-host disease. Athersys has additional pharmaceutical programs in the metabolic and neurological areas, and a broad international network of collaborations with leading clinical and research institutions.
ATHX:NASDAQ

Expert Comments:

Jefferson Research (4/8/16)
"Athersys Inc. is showing strong cash flow quality, operating efficiency, balance sheet quality and earnings quality, and valuation suggests a lower amount of price risk. . .the company's ability to earn a profit is in part the result of how rapidly it converts its collection of assets into revenues and the resulting percentage available in earnings and cash flow after expenses have been paid. . .the balance sheet shows the ability of Athersys to pay its bills and fund future growth."

Maxim Jacobs, Edison Investment Research (3/24/16)
"Athersys Inc. recently signed a partnership agreement with Healios in Japan for stroke and other indications. A Phase 2 trial with MultiStem in acute myocardial infarction is underway with data expected in H2/16, and a Phase 2a study for acute respiratory distress syndrome will be initiated soon."

Jason Kolbert, Maxim Group (3/11/16)
"Given the building data that suggests Athersys Inc.'s MultiStem works (and that stem cell therapy works in multiple modalities), we are lowering our risk rating (to 20%, from 30%). This drives a price target increase to $10, from $5. While the challenge in reaching our price target remains the catalyst (a 2017 event), we believe that smart investors who take the time to evaluate the data will see that a positive outcome for MultiStem in stroke is probable."

Maxim Jacobs, Edison Investment Research (3/4/16)
"The announcement on Jan. 8 of a new partnership between Athersys Inc. and Healios follows less than three months after a similar Japanese licensing deal with Chugai ended. The new deal represents an improvement and increases fees and milestone payments from $205M to $230M for the stroke program and royalties in the double digits to high teens."

Maxim Jacobs, Edison Investment Research (2/25/16)
"Athersys Inc. is developing MultiStem, an allogeneic, bone marrow-derived stem cell product. Results from a 140-patient Phase 2 study in ischemic stroke revealed a potential benefit when dosed <36 hours post stroke. . .the company recently signed a partnership agreement with Healios in Japan for stroke and other indications. A Phase 2 trial with MultiStem in acute myocardial infarction is underway with data expected in H2/16, and a Phase 2a study for acute respiratory distress syndrome (ARDS) will be initiated soon."

Jason Kolbert, Maxim Group (2/17/16)
"Athersys Inc. announced that the one-year follow-up data from the phase II stroke study showed that patients receiving MultiStem (N=65) continued to improve and had a statistically significant higher rate of 'Excellent Outcome' (P=0.02) versus placebo (N=61). . .the company continues to demonstrate that MultiStem has a meaningful clinical benefit in patients who have suffered an ischemic stroke and may extend the therapeutic window to 36 hours."

More Expert Comments

Experts Following This Company

Katherine Genis, Analyst – Edison Investment Research
Christian Glennie – Edison Investment Research
Maxim Jacobs – Edison Investment Research
Jason Kolbert, Senior Analyst – Maxim Group
Jason McCarthy, Analyst – Maxim Group
Henry McCusker, Founder and Director of Research – Scimitar Equity
Henry McCusker RegMed Investors
Ram Selvaraju, Managing Director; Head of Healthcare Equity Research – Rodman & Renshaw

The information provided above is from analysts, newsletters, the company and other contributors.

Athersys Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.